



## BioDelivery Sciences to Report Third Quarter 2018 Financial Results on November 8, 2018

October 23, 2018

RALEIGH, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that it will report its third quarter 2018 financial results after the close of the U.S. financial markets on Thursday, November 8, 2018. The company will host a conference call at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.

### Conference Call Dial In & Webcast Information:

Date: Thursday, November 8, 2018  
Time: 4:30 PM Eastern Time  
Domestic: 800-479-1004  
International: 323-794-2599  
Passcode: 9394131  
Webcast: <http://public.viavid.com/index.php?id=131852>

Replays available through November 22, 2018

Domestic: 844-512-2921  
International: 412-317-6671  
Conference ID: 9394131

### About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (BDSI) is a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, and opioid dependence. BDSI's headquarters is in Raleigh, North Carolina.

For more information, please visit or follow us:

Internet: [www.bdsi.com](http://www.bdsi.com)  
Facebook: [Facebook.com/BioDeliverySI](https://www.facebook.com/BioDeliverySI)  
Twitter: [@BioDeliverySI](https://twitter.com/BioDeliverySI)

BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences. For full prescribing information and important safety information on BDSI products please visit [www.bdsi.com](http://www.bdsi.com) where the Company promptly posts press releases, SEC filings, and other important information or contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visit [www.belbuca.com](http://www.belbuca.com) and for full prescribing and safety information on BUNAVAIL, please visit [www.bunavail.com](http://www.bunavail.com).

© 2018 BioDelivery Sciences International, Inc. All rights reserved.

### CONTACTS:

#### Investors:

Mary Coleman  
Vice President, Investor & Public Relations  
919-582-9050  
[mcoleman@bdsi.com](mailto:mcoleman@bdsi.com)

Monique Kosse  
Managing Director  
LifeSci Advisors  
212-915-3820  
[monique@lifesciadvisors.com](mailto:monique@lifesciadvisors.com)



Source: BioDelivery Sciences International, Inc.